Clinical trials: Chronic Nephropathy
Chronic Kidney Diseases, Acute Kidney Injury
Nova Max Creatinine and eGFR Meter System
To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on venous, and capillary blood and compare the…
- Trial name
- NCT05118074
- Testing
- Creatinine, eGFR
- Where
- 3 sites in United States
- Volunteers
- 360 people
- Sponsor
- Nova Biomedical
Chronic Kidney Diseases, Protein-Energy Malnutrition
Effect of a Specialized Oral Supplement on Nutritional Status and Quality of Life in Non-dialysis CKD
Patients whit chronic kidney disease (CKD) there is a high prevalence of nutritional disorders and negative changes in body composition, which is strongly associated with an increased risk of morbidity and mortality.
- Trial name
- NCT06576479
- Testing
- Nutritious Shake, Nutritional counseling
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- NIN Institute
Anemia, Dialysis-Dependent Chronic Kidney Disease
Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
This is a Phase 3 Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
- Trial name
- TRILOGY (NCT03242967)
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- United States
- Sponsor
- Akebia Therapeutics
End Stage Renal Disease
Acid-Base Composition With Use of hemoDialysates
This study is a prospective, single center, single blind (patient and laboratory), randomized, cross-over, two week investigation of intradialytic acid-base kinetics and physiology associated with use of two commercial acid…
- Trial name
- ABChD (NCT02334267)
- Testing
- Group 1: GranuFlo, Group 2: NaturaLyte
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Fresenius Medical Care North America
Hyperphosphatemia, End Stage Renal Disease
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
The purpose of the study is to determine the effect and optimum dose and evaluate the safety of ferric citrate, administered three times daily (TID) immediately after meals for a total daily dose of 4 or 6 grams for 56 days, on…
- Conditions
- Hyperphosphatemia, End Stage Renal Disease, ESRD
- Trial name
- NCT01503736
- Testing
- ferric citrate
- Where
- 5 sites in Taiwan
- Volunteers
- 183 people
- Sponsor
- Panion & BF Biotech Inc.
Chronic Kidney Disease(CKD)
Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects
The study was designed to evaluate the pharmacokinetic effects of itraconazole and rifampicin on HRS-1780 after oral administration of HRS-1780 tablets in healthy subjects
- Trial name
- NCT06344936
- Testing
- HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Secondary Hyperparathyroidism
A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416
This was a multiple-dose, double-blind, randomized, placebo-controlled study. Chinese subjects residing in Mainland China with chronic kidney disease (CKD) receiving hemodialysis were randomized in a 3:1 ratio to receive 5 mg…
- Trial name
- NCT03283098
- Testing
- Etelcalcetide
- Where
- 5 sites in China
- Volunteers
- 33 people
- Sponsor
- Amgen
Chronic Kidney Disease, Healthy Volunteers
A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD). The kidneys filter extra water and waste out of the blood and make urine.
- Trial name
- NCT05800444
- Testing
- BAY3283142
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Anemia of Chronic Kidney Disease
Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Anticalin® proteins are engineered human proteins that are able to bind specific target molecules. The Anticalin PRS-080#022-DP to be investigated in this study is directed against hepcidin and is intended for the treatment of…
- Trial name
- NCT03325621
- Testing
- PRS-080#022-DP
- Where
- 6 sites in Czechia, Germany
- Volunteers
- 11 people
- Sponsor
- Pieris Pharmaceuticals GmbH
Chronic Kidney Disease
Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment
Researchers are looking for a better way to treat people with chronic kidney diseases. Before a treatment can be approved for patients to take, researchers do clinical studies to better understand its safety and what happens to…
- Trial name
- NCT04820621
- Testing
- Runcaciguat (BAY1101042)
- Where
- Germany
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Bayer
Anaemia
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.
- Trial name
- NCT03409107
- Testing
- Daprodustat (GSK1278863), Iron therapy
- Where
- 168 sites in United States, Argentina and 12 more
- Volunteers
- 614 people
- Sponsor
- GlaxoSmithKline
End-Stage Renal Disease (ESRD)
Improvement of EPO-resistance in Hemodialysis Patients With Chronic Inflammation by High Cut-off Hemodialysis
Chronic inflammation in dialysis patients is linked to cardiovascular mortality and clinical signs and symptoms, like the impaired response to erythropoiesis-stimulating agents (ESAs).
- Trial name
- CIEPO-PILOT (NCT01526798)
- Testing
- Theralite (high cut-off hemodialysis), Conventional high-flux dialyzer
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Vantive Health LLC
Anemia, Chronic Kidney Disease
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.
- Trial name
- NCT01906489
- Testing
- AKB-6548
- Where
- 47 sites in United States
- Volunteers
- 210 people
- Sponsor
- Akebia Therapeutics
Chronic Kidney Disease, Type 2 Diabetes
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy
- Trial name
- NCT00811889
- Testing
- Bardoxolone Methyl (RTA 402)
- Where
- 42 sites in United States
- Volunteers
- 227 people
- Sponsor
- Biogen
Renal Anemia of Chronic Kidney Disease
Observational Study of MIRCERA in Users of Self-Application and Multidose Systems
This non-interventional, observational study investigates the efficiency, safety and acceptance of MIRCERA in participants, who received erythropoiesis stimulating agent (ESA) using a self-application system.
- Trial name
- NCT02540213
- Testing
- MIRCERA
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- Hoffmann-La Roche
Renal Impairment, Healthy
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.
- Conditions
- Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)
- Trial name
- NCT07165015
- Testing
- LY3537031
- Where
- 4 sites in United States, New Zealand
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System
The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with…
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Poor Vascular Access
- Trial name
- NCT06037265
- Testing
- PAVmed PortIO™ Intraosseous Infusion System
- Where
- 4 sites in Colombia
- Volunteers
- 15 people
- Sponsor
- PAVmed Inc.
Renal Impairment, Renal Disease
Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function
Renal insufficiency is common in participants with blood cancers. The main objective of this study is to evaluate adverse events and movement of oral venetoclax tablets through the body of female participants with severe normal…
- Trial name
- NCT04810598
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Chronic Allograft Nephropathy, Chronic Kidney Disease
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
Hyperparathyroidism (HPT) is common in people with a kidney transplant. Patients with HPT often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the neck.
- Conditions
- Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism
- Trial name
- NCT00975000
- Testing
- Cinacalcet
- Where
- 51 sites in United States, Australia and 9 more
- Volunteers
- 114 people
- Sponsor
- Amgen
Anemia in Chronic Kidney Disease
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
The primary purpose of this study is to evaluate efficacy and safety of FG-4592 in the correction of anemia in non-dialysis chronic kidney disease patients.
- Trial name
- NCT01599507
- Testing
- FG-4592
- Where
- 13 sites in China
- Volunteers
- 91 people
- Sponsor
- Kyntra Bio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.